KPT-8602 manufacturers
- Eltanexor
-
- $60.00
-
2026-06-02
- CAS:1642300-52-4
- Purity: 99.86%
- Supply Ability: 10g
- Eltanexor
-
- $60.00
-
2026-06-02
- CAS:1642300-52-4
- Purity: 99.86%
- Supply Ability: 10g
|
| | KPT-8602 Basic information |
| Product Name: | KPT-8602 | | Synonyms: | KPT-8602;Eltanexor
(KPT-8602;CS-2388;KPT-8602 (KPT 8602;5-Pyrimidineacetamide, α-[[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]methylene]-, (αE)-;(E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide;ATG-016;ONO-7706 | | CAS: | 1642300-52-4 | | MF: | C17H10F6N6O | | MW: | 428.3 | | EINECS: | | | Product Categories: | | | Mol File: | 1642300-52-4.mol |  |
| | KPT-8602 Chemical Properties |
| Boiling point | 574.4±60.0 °C(Predicted) | | density | 1.57±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | pka | 13.06±0.50(Predicted) | | color | Off-white to light yellow |
| | KPT-8602 Usage And Synthesis |
| Uses | (αE)-α-[[3-[3,5-bis(Trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]methylene]-5-pyrimidineacetamide is an exportin-1 inhibitor with anti-leukemic activity. Exportin-1 mediates nuclear trafficking of proteins. (αE)-α-[[3-[3,5-bis(Trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]methylene]-5-pyrimidineacetamide can be used to develop treatments for acute lymphoblastic leukemia. | | in vivo | KPT-8602 (15 mg/kg; oral gavage; daily for 12 days) shows potent anti-lymphoblastic leukemia activity[1]. | Animal Model: | Female BALB/c mice (model with the JAK3 (M511I) mutation)[1] | | Dosage: | 15 mg/kg | | Administration: | Oral gavage; daily for 12 days | | Result: | Showed a marked reduction in total white blood cell (WBC) counts after 2 days of treatment compared to placebo-treated animals and the WBC counts continued to drop until they reached normal levels (<10,000 cells/μL) by day 12. |
|
| | KPT-8602 Preparation Products And Raw materials |
|